Advertisement
ADVANCED SEARCH

This Article Figures Only Full Text Full Text (PDF) Résumé Online Appendix Submit a response View responses Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Setoguchi, S. Articles by Schneeweiss, S. Search for Related Content PubMed PubMed Citation Articles by Setoguchi, S. Articles by Schneeweiss, S. Related Collections Heart failure Related Articles

Maximum potential benefit of implantable defibrillators in preventing sudden death after hospital admission because of heart failure

From the Division of Pharmacoepidemiology and Pharmacoeconomics (Setoguchi, Rassen, Schneeweiss) and the Advanced Heart Disease Section, Division of Cardiovascular Medicine (Nohria, Stevenson), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA

Correspondence to: Dr. Soko Setoguchi, Division of Pharmacoepidemiology and Pharmacoeconomics, 3030–1620 Tremont St., Boston MA 02130, USA; fax 617 232-8602; ssetoguchi{at}partners.org

Background: Implantable defibrillators are recommended for the prevention of sudden cardiac death in patients with heart failure. However, criteria to identify those who would benefit most from this therapy are lacking. We assessed the maximum potential benefit of preventing sudden death in patients with repeated hospital admissions because of heart failure.

Methods: Using a cohort assembled from an administrative database, we identified 14 374 patients admitted to hospital for the first time because of heart failure between Jan. 1, 2000, and Dec. 31, 2004. We followed subsequent admissions related to heart failure as well as mortality and causes of death to Mar. 31, 2006. We regarded all out-of-hospital cardiac deaths as sudden deaths. We calculated the maximum potential benefit of preventing sudden death by subtracting the observed survival after each hospital admission from the hypothetical survival whereby all out-of-hospital cardiac deaths were assumed to be preventable.

Results: The mean age of the cohort was 77 years, 45% were women, 11% had cerebrovascular disease, and 21% had chronic kidney disease. Out-of-hospital cardiac deaths constituted 13.7% (1226/8967) of all deaths during 32 055 person-years of follow-up. The median survival declined with each subsequent hospital admission related to heart failure. The hypothetical prevention of all out-of-hospital deaths prolonged life by 0.63 (95% confidence interval [CI] 0.49 to 0.77) years after the first hospital admission. This potential benefit dropped to 0.28 (95% CI 0.10 to 0.46) years after 3 hospital admissions related to heart failure. Among patients less than 65 years old, and older patients without kidney disease, dementia or cancer, more than 50% survived longer than 2 years until they had 2 or 3 hospital admissions related to heart failure.

Interpretation: The use of implantable defibrillators to prevent sudden death would provide limited benefit among older patients with comorbidities and among patients with multiple hospital admissions related to heart failure.

This article has been cited by other articles:

				P. Dorian Effective and efficient use of implantable defibrillators: Sometimes it's over when it's over Can. Med. Assoc. J., March 17, 2009; 180(6): 599 - 600. [Full Text] [PDF]

eLetters:

HOME	CURRENT ISSUE	PAST ISSUES	COLLECTIONS	HELP	SEARCH
Copyright 1995-2009, Canadian Medical Association. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p) All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.